


Supplementary Figure. 1. Trend in b/tsDMARDs prescription.
Bar charts showing the percentages of prescribed b/tsDMARDs in each year.


A

Naïve



B


Switch



Supplementary Figure 2. Treatment outcomes of b/tsDMARDs.

A and B. Averaged treatment response comparing each MOA from baseline to 12 months. Left panel: DAS28-CRP, middle panel: CDAI, right panel: HAQ. Upper dotted line in DAS28-CRP: 2.7, lower dotted line in DAS28-CRP: 2.3, upper dotted line in CDAI: 10, lower dotted line in CDAI: 2.8, dotted line in HAQ: 0.5. A. b/tsDMARD-naïve patients. B. Switched patients.

Supplementary Fig. 2



Supplementary Figure 3. Selection of the initial b/tsDMARDs for naïve patients and MOA selection pattern at the time of switching. Sankey diagram showing retention or switching of b/tsDMARDs initiated in KURAMA cohort for naïve patients, and the choice of MOA at the time of switching. The diagram shows the first through the fourth b/tsDMARDs. MOA: mode of action. Supplementary Fig. 3